Table 1 Baseline characteristics of patients
From: Study on risk factors and associated drug related problems in patients with stroke
Baseline Category | Type of stroke | Total | P value | |
|---|---|---|---|---|
Ischemic n=(76) N (%) | Hemorrhagic N= (35) n (%) | (N = 111) | ||
Age of the patients in yrs, Median (IQR) | 62 (49–71) | 57 (46–70) | 60 (49–71) | 0.601a |
18–35 | 6 (7.9) | 4 (11.40) | 10 (9.0) | 0.74b |
36–64 | 37 (48.7) | 18 (51.4) | 55 (49.5) | |
≥ 65+ | 33 (43.4) | 13 (37.1) | 46 (41.4) | |
Gender | 0.92c | |||
Male | 58 (76.3) | 27 (77.1) | 85 (76.6) | |
Female | 18 (23.7) | 8 (22.9) | 26 (23.4) | |
Comorbidities | ||||
Hypertension | 44 (57.9) | 24 (68.6) | 68 (61.3) | 1.00c |
Diabetes | 23 (30.3) | 7 (20.0) | 30 (27.0) | 0.25c |
Atrial Fibrillation | 5 (6.6) | 0 (0.0) | 5 (4.5) | 0.17b |
Hyperlipidemia | 21 (27.6) | 3 (8.6) | 24 (21.6) | 0.02c* |
Other Cardiac disease | 1 (1.3) | 1 (2.9) | 2 (1.8) | 0.53b |
Others | 19 (25.0) | 8 (22.9) | 27 (24.3) | 0.80c |
Previous TIA | 2 (2.6) | 0 (0.0) | 2 (1.8) | 1.00b |
Previous Stroke | 14 (18.4) | 7 (20.0) | 21 (18.9) | 0.84c |
Family History of Stroke | 7 (9.2) | 3 (8.6) | 10 (9.0) | 0.91c |
History of Smoking | 0.29b | |||
Never Smoker | 58 (76.3) | 31 (88.6) | 89 (80.2) | |
Current Smoker | 14 (18.4) | 4 (11.4) | 18 (16.2) | |
Former Smoker | 4 (5.3) | 0 (0.0) | 4 (3.6) | |
Alcohol Consumption | 0.92b | |||
None | 61 (80.3) | 28 (80.0) | 89 (80.2) | |
Occasional | 5 (6.6) | 3 (8.6) | 8 (7.2) | |
Mild | 1 (1.3) | 0 (0.0) | 1 (0.9) | |
Heavy | 5 (6.6) | 3 (8.6) | 8 (7.2) | |
Former Drinker | 4 (5.3) | 1 (2.9) | 5 (4.5) | |
Anti-Hypertensive drug | ||||
Calcium Channel Blockers | 17 (22.4) | 16 (45.7) | 33 (29.7) | 0.01c* |
Angiotensin Receptor Blocker | 21 (27.6) | 12 (95.3) | 33 (29.7) | 0.01b* |
Angiotensin Converting Enzyme Inhibitors | 1 (1.3) | 0 (0.0) | 1 (0.9) | 1.00b |
Diuretics | 6 (7.9) | 6 (17.2) | 12 (10.8) | 0.17b |
Beta-Blockers | 11 (15.5) | 10 (28.6) | 21 (18.9) | 0.07b |
Alpha-Blockers | 3 (3.9) | 6 (17.1) | 9 (8.1) | 0.03b* |
Combination Antihypertensive Drug | 11 (14.4) | 4 (11.5) | 15 (13.5) | 0.5b |
Anti-Diabetics | ||||
Insulin | 2 (2.6) | 0 (0.0) | 2 (1.8) | 1.00b |
Biguanides | 5 (6.6) | 4 (11.4) | 9 (8.1) | 0.5b |
Sulfonylureas | 4 (5.3) | 1 (2.9) | 5 (4.5) | 1.00b |
Alpha-Glucosidase Inhibitors | 4 (5.2) | 0 (0.0) | 4 (3.6) | 1.00b |
DPP-4 Inhibitors | 1 (1.3) | 3 (8.6) | 4 (3.6) | 0.09b |
Combination Antidiabetic drug | 13 (17.1) | 0 (0.0) | 13 (11.7) | 0.03b* |
HMG-CoA Reductase Inhibitors | 73 (96.0) | 7 (20.0) | 80 (72.0) | 0.00c* |
Surgical Management | 4 (5.3) | 6 (17.1) | 10 (9.0) | 0.07b |